STOCK TITAN

AVROBIO to Present at the JMP Securities Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

AVROBIO (Nasdaq:AVRO), a clinical-stage gene therapy company, announced that its president and CEO, Geoff MacKay, will present at the JMP Securities Life Sciences Conference on June 17, 2021, at 10:30 a.m. ET. A live webcast will be accessible on the Company's website, with an archived recording available for 90 days. AVROBIO aims to provide personalized gene therapy to combat genetic diseases using its plato® gene therapy platform. The company is advancing clinical programs for Fabry disease, Gaucher disease type 1, and cystinosis, and is headquartered in Cambridge, Massachusetts.

Positive
  • None.
Negative
  • None.

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the JMP Securities Life Sciences Conference at 10:30 a.m. ET on Thursday, June 17, 2021.

A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors & Media section of the Company's website at www.avrobio.com. An archived webcast recording of the presentation will be available on the website for approximately 90 days.

About AVROBIO

Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by our industry leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Forward-Looking Statement

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our prospective product candidates, results of preclinical studies, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, the timing of patient recruitment and enrollment activities, and product approvals, anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, timing and likelihood of success, and the expected benefits and results of our implementation of the plato® platform in our clinical trials and gene therapy programs, including the use of a personalized and ultra-precision busulfan conditioning regimen. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato® platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

FAQ

When is AVROBIO's presentation at the JMP Securities Life Sciences Conference?

AVROBIO's presentation is scheduled for June 17, 2021, at 10:30 a.m. ET.

How can I access the webcast for AVROBIO's presentation?

The live webcast can be accessed under 'Events and Presentations' on AVROBIO's website.

What is the focus of AVROBIO's gene therapy pipeline?

AVROBIO focuses on personalized gene therapy targeting genetic diseases, including clinical programs for Fabry disease, Gaucher disease type 1, and cystinosis.

What is the plato® gene therapy platform?

The plato® gene therapy platform is AVROBIO's proprietary technology designed to deliver gene therapy worldwide with durable expression of therapeutic proteins.

Where is AVROBIO headquartered?

AVROBIO is headquartered in Cambridge, Massachusetts, with an office in Toronto, Ontario.

AVROBIO, Inc.

NASDAQ:AVRO

AVRO Rankings

AVRO Latest News

AVRO Stock Data

62.85M
44.89M
0.4%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE